AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00926536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSA only
Description: DSA imaging only
Study NCT04273932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium aspartate of lithium carbonate will be administered by mouth.
Study NCT02009371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light therapy
Description: In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
Study NCT02009371 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim Red Light therapy
Description: In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
Study NCT04565821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPD Probe via TNIT
Description: A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
Study NCT04687566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study NCT04687566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study NCT04687566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and memantine
Description: The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study NCT04687566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
Study NCT02922075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Description: A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
Study NCT02922075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen matrix graft
Description: A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant
Description: A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate implant
Description: A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
Study NCT02922075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
Study NCT02922075 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tooth extraction
Description: Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate restoration
Description: A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate restoration
Description: A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
Study NCT02922075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone regeneration
Description: All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
Study NCT02922075 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bone regeneration
Description: All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
Study NCT02922075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post operative medication
Description: Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
Study NCT02922075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Post operative medication
Description: Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definitive prosthesis
Description: Definitive implant-supported restorations were performed 6 months after dental implant placement.
Study NCT02922075 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Definitive prosthesis
Description: Definitive implant-supported restorations were performed 6 months after dental implant placement.
Study NCT02922075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No soft tissue graft
Description: No soft tissue graft was used
Study NCT02166749 — intervention group
Intervention type: PROCEDURE
Intervention: Subtotal abdominal hysterectomy
Description: Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
Study NCT02070978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
Study NCT02070978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
Study NCT02070978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
Study NCT01643278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01643278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01643278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01643278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02572856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
Study NCT03762005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
Study NCT03762005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactate guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
Study NCT04187430 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prospective
Description: After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
Study NCT03311269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariVein RES
Description: ClariVein system
Study NCT03311269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulfate 1% Injection
Description: Sodium Tetradecyl Sulfate STS 1% Injection
Study NCT03311269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulfate 3% Injection
Description: Sodium Tetradecyl Sulfate 3% Injection
Study NCT00935259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 40 mg once daily for 2 weeks
Study NCT00935259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg once daily for 2 weeks
Study NCT00935259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Study NCT00935259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
Study NCT01051102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
Study NCT01051102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation I
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation II
Study NCT01505179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
Study NCT01505179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
Study NCT02156973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video information
Description: A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
Study NCT02773277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-impulse testing
Description: all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
Study NCT00934856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
Study NCT00934856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
Study NCT00934856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation III
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation IV
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation V
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation VI
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Control
Description: Control
Study NCT00937521 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine with antipyretic
Description: Vaccine candidate formulation I with antipyretic
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Study NCT00901979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT01483989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® Gel Drop lubricant eye gel
Description: SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
Study NCT01135030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee
Description: Primary Total knee
Study NCT02023905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus at 10 mg daily continuously
Study NCT02023905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
Study NCT03195049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood group,complete blood count
Description: measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
Study NCT02101658 — intervention group
Intervention type: OTHER
Intervention: clinic-based weight measurements
Study NCT04573556 — intervention group
Intervention type: DRUG
Intervention: Lemborexant
Description: Lemborexant oral tablets.
Study NCT02599493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
Study NCT02599493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
Study NCT01675310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy + metformin
Study NCT01675310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical nutrition therapy
Description: medical nutrition therapy
Study NCT00004445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT00004445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS-8
Study NCT00968006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily for 4 weeks
Study NCT02719925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mg(+)
Description: * 1,5 L per day during 30 days~* No livestyle counseling
Study NCT02719925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mg(-)
Description: 1,5 L water per day during 30 days No lifestyle counseling
Study NCT00237211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT03946098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: A newly developed iCBT protocol targeting problem gambling.
Study NCT00831012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3delta30/31-7164
Description: A live attenuated, recombinant DEN3 candidate vaccine virus
Study NCT01200927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Perceptual motor therapy, comparing twice weekly to once weekly home program
Study NCT00716547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 50 mg (b.i.d.)
Study NCT00716547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 100 mg (b.i.d.)
Study NCT00716547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: b.i.d.
Study NCT00716547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 100 mg (b.i.d.)
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: pSG2.HIVconsv DNA vaccine
Description: pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
Study NCT02425241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv DNA vaccine
Description: pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.